Empagliflozin as add-on to pioglitazone with or without metformin in patients with Type 2 diabetes

被引：0
|
作者：
Kovacs, C. S. [1 ]
Seshiah, V. [2 ]
Merker, L. [3 ]
Christiansen, A. Vedel [4 ]
Roux, F. [5 ]
Salsali, A. [6 ]
Kim, G. [6 ]
Stella, P. [6 ]
Woerle, H. J. [6 ]
Broedl, U. C. [6 ]
机构：
[1] Mem Univ Newfoundland, Hlth Sci Ctr, St John, NF A1C 5S7, Canada
[2] Diabet Care & Res Inst, Chennai, Tamil Nadu, India
[3] Diabet & Nierenzentrum, Dormagen, Germany
[4] Boehringer Ingelheim Danmark AS, Copenhagen, Denmark
[5] Boehringer Ingelheim France, Reims, France
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
来源：
DIABETIC MEDICINE | 2015年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P190
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [31] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin Plus Sulfonylurea (SU) in Patients with Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Vedel, Anita
    Roux, Christiansen Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A280 - A280
  • [32] Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea
    P. Khaloo
    S. Asadi Komeleh
    H. Alemi
    M. A. Mansournia
    A. Mohammadi
    A. Yadegar
    M. Afarideh
    S. Esteghamati
    M. Nakhjavani
    A. Esteghamati
    Journal of Endocrinological Investigation, 2019, 42 : 851 - 857
  • [33] Pleiotropic effects of add-on therapy with pioglitazone, metformin or the combination of both in patients with type 2 diabetes on stable insulin glargine therapy
    Kleine, I. E.
    Fuchs, W.
    Pfuetzner, A.
    Forst, T.
    Hanefeld, M.
    DIABETOLOGIA, 2011, 54 : S374 - S374
  • [34] Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea
    Khaloo, P.
    Komeleh, S. Asadi
    Alemi, H.
    Mansournia, M. A.
    Mohammadi, A.
    Yadegar, A.
    Afarideh, M.
    Esteghamati, S.
    Nakhjavani, M.
    Esteghamati, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (07) : 851 - 857
  • [35] Empagliflozin (EMPA) Compared with Glimepiride (GLIM) as Add-on to Metformin (MET) for 2 Years in Patients with Type 2 Diabetes (T2DM)
    Ridderstrale, Martin
    Andersen, Knut Robert
    Zeller, Cordula
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A70 - A70
  • [36] Comparative Study on Efficacy of Empagliflozin Versus Sitagliptin, as an Add-on Therapy to Metformin in Type 2 Diabetic Patients
    Salankar, Harsh
    Rode, Sonali
    Arjun, C.
    Joseph, Rajeeta
    Deshmane, Gourav B.
    Vijayan, Radhika P.
    JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2024, 16 : S335 - S338
  • [37] Empaglilozin compared with glimepiride as add-on to metformin for 2 years in patients with type 2 diabetes
    Ridderstrale, M.
    Andersen, K. R.
    Zeller, C.
    Kim, G.
    Woerle, H. J.
    Broedl, U. C.
    DIABETOLOGIA, 2014, 57 : S7 - S8
  • [38] Dapagliflozin plus Saxagliptin Add-On vs. Glimepiride Add-On to Metformin in Patients with Poorly Controlled Type 2 Diabetes
    Frias, Juan P.
    Gonzalez-Galvez, Guillermo
    Johnsson, Eva K.
    Maaske, Jill
    Peters, Anne
    DIABETES, 2018, 67
  • [39] Dapagliflozin as an add-on to metformin lowers hyperglycaemia in type 2 diabetes patients inadequately controlled with metformin alone
    Bailey, C. J.
    Gross, J. L.
    Bastone, L.
    Bastien, A.
    List, J. F.
    DIABETOLOGIA, 2009, 52 : S76 - S76
  • [40] IMPROVED GLYCEMIC CONTROL WITH INSULIN GLARGINE VERSUS PIOGLITAZONE AS ADD-ON THERAPY TO SULFONYLUREA OR METFORMIN IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES MELLITUS
    Meneghini, Luigi F.
    Traylor, Louise
    Schwartz, Sherwyn L.
    ENDOCRINE PRACTICE, 2010, 16 (04) : 588 - 599
12345